EGFR and gastric cancer: In this study, it is showed that integrin β4 may be one of the branches to regulate the drug sensitivity in gastric cancer (adenocarcinoma), which is consistent with previous report that integrin β4 interacts with EGFR in a ligand independent manner and overexpression of integrin β4 induces drug resistance of hepatocellular carcinoma [13].